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Abstract
The drug-metabolizing enzyme thiopurine methyltransferase (TPMT) has become one of the best
examples of pharmacogenomics to be translated into routine clinical practice. TPMT metabolizes
the thiopurines 6-mercaptopurine, 6-thioguanine, and azathioprine, drugs that are widely used for
treatment of acute leukemias, inflammatory bowel diseases, and other disorders of immune
regulation. Since the discovery of genetic polymorphisms in the TPMT gene, many sequence
variants that cause a decreased enzyme activity have been identified and characterized.
Increasingly, to optimize dose, pretreatment determination of TPMT status before commencing
thiopurine therapy is now routine in many countries. Novel TPMT sequence variants are currently
numbered sequentially using PubMed as a source of information; however, this has caused some
problems as exemplified by two instances in which authors’ articles appeared on PubMed at the
same time, resulting in the same allele numbers given to different polymorphisms. Hence, there is
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an urgent need to establish an order and consensus to the numbering of known and novel TPMT
sequence variants. To address this problem, a TPMT nomenclature committee was formed in
2010, to define the nomenclature and numbering of novel variants for the TPMT gene. A website
(http://www.imh.liu.se/tpmtalleles) serves as a platform for this work. Researchers are encouraged
to submit novel TPMT alleles to the committee for designation and reservation of unique allele
numbers. The committee has decided to renumber two alleles: nucleotide position 106 (G > A)
from TPMT*24 to TPMT*30 and position 611 (T > C, rs79901429) from TPMT*28 to TPMT*31.
Nomenclature for all other known alleles remains unchanged.
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Introduction
The thiopurines 6-thioguanine, 6-mercaptopurine (6-MP), and its pro-drug azathioprine are
purine based analogues. These drugs were synthesized in the early 1950’s by Elion and
Hitchings [1], and within a few years 6-MP was used to successfully treat children with
childhood acute lymphoblastic leukemia (ALL) [2]. Today, thiopurines continue to be used
extensively in clinical practice as anticancer and immunosuppressive agents despite having a
narrow therapeutic index with potential life-threatening drug induced toxicity.
One of the main causes of toxicity is the way in which these prodrugs are metabolized to
their active metabolites inside the cell [3,4]. They undergo extensive metabolism to form
both active and inactive metabolites causing cell death by several different mechanisms [4].
The main causes of cytotoxicity are through the incorporation of thioguanine nucleotides
(TGNs) into the DNA as base analogues [5], inhibition of de novo purine synthesis [6,7],
and disturbances in intracellular signaling pathways. The latter of these contributes to the
immunosuppressive properties of these agents [8–10]. Thiopurines are S-methylated by the
enzyme thiopurine methyltransferase (TPMT, EC 2.1.1.67). This produces methylated
metabolites such as S-methylmercaptopurine and S-methylthioguanine, both of which are
believed to be inactive, and S-methyl-thioinosine monophosphate, an inhibitor of de novo
purine synthesis, emphasizing the importance of TPMT activity in the metabolism of these
drugs.
The first study measuring TPMT activity in humans by Weinshilboum and Sladek
demonstrated trimodal distribution [11]. They reported that from a cohort of 298 randomly
selected Caucasians, 11.1% had intermediate activity, 89.6% had high activity, and 0.3%
had no activity. This was critical in helping to understand the role of TPMT activity in
patients treated with thiopurines and was highlighted by Lennard [12], who showed that in
children treated with 6-MP for ALL, the red blood cell TGN concentrations were inversely
correlated to the TPMT activity, indicating that with high TPMT activity more drug was S-
methylated to inactive metabolites.
Following the study of TPMT activity, the cloning and characterization of the human TPMT
cDNA revealed that these phenotypic variations were primarily due to variation within the
coding sequence of the gene itself [13,14]. The human TPMT gene maps to chromosome
6p22.3, which is 34 kb in length and consists of 10 exons. An untranscribed and untranslated
pseudogene, homologous to 96% of the TPMT cDNA sequence, has been located to
chromosome 18 [15]. To date, about 30 genetic variants have been shown to affect TPMT
protein stability and/or enzymatic activity. Most are nonsynonymous single nucleotide
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polymorphisms (SNPs, Table 1, Fig. 1). The most intensively studied alleles are *2, *3A,
and *3C, which represent up to 95% of variant alleles found in most populations [16–18].
However, large interethnic differences exist in the frequencies of these alleles, and in the
prevalence of more rare alleles. Examples are TPMT*8 and TPMT*6, which occur at
frequencies between 1.5 and 3.5% in some African and Asian populations [19,20], but very
rarely, if at all, in other investigated populations. More detailed information about specific
TPMT alleles can be found in Wang et al.’s [21] study. In the future, the application of
routine exome or whole genome sequencing is likely to unveil many more rare TPMT
sequence variants [22].
Patients inheriting two nonfunctional TPMT alleles are at the highest risk of hematopoietic
toxicity if treated with conventional doses of thiopurines (essentially 100% risk), and
convert more parent drug into active TGNs because they lack the methylation pathway,
whereas patients who inherit one wild-type allele and one nonfunctional allele are at a
significantly higher risk of hematopoietic toxicity (~35% cumulative incidence in one study
of children with ALL) [23,24].
In contrast to this, ALL patients with high TPMT activity may have a higher risk of relapse
if treated with conventional doses of 6-MP (depending on what other ALL therapy they
receive); thus, they should be treated on full-dose thiopurine. Those with intermediate
activity often require treatment with a lower dose to avoid toxicity. It has been shown that
TPMT heterozygous ALL patients do not have a higher risk of ALL relapse if treated with a
lower dose of 6-MP [25], and that heterozygous ALL patients have a significantly lower rate
of minimal residual disease positivity for early treatment response to 6-MP, at least in the
ALL Berlin-Frankfurt-Münster (BFM) trial [26].
Clearly, as this enzyme has such a profound effect on drug metabolism, it is critical that the
TPMT status of a patient should be taken into account before commencing thiopurine
treatment [27].
In 2011, a guideline from the Clinical Pharmacogenetics Implementation Consortium was
published, with the purpose of providing information with which to interpret clinical TPMT
genotype tests so that the results can be used successfully to guide the dosing of thiopurines
[28].
Although there is still debate on genotype versus phenotype in assessing the TPMT status, it
remains both timely and critical that a repository for the naming of these polymorphisms is
created. This will have appropriate links to existing resources: thus, investigators in the field
can easily identify polymorphisms that have been described previously and their effects on
TPMT activity. It is to this end that a new TPMT nomenclature website (http://
www.imh.liu.se/tpmtalleles) was launched by representatives from a worldwide group of
researchers from the field of TPMT pharmacogenetic research.
The TPMT nomenclature website
Since the publication of the first TPMT variant (allele *2) in 1995 [13,14], many sequence
variants in the TPMT gene have been identified and been given star (*) allele numbers
(summarized in Table 1, Fig. 1). Currently, authors number alleles sequentially using
PubMed as a source of information about the last published allele; however, this has caused
some problems, as exemplified by two instances in which authors’ articles appeared on
PubMed at the same time, resulting in the same number being given to different
polymorphisms.
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To circumvent this in the future, there is a need for a unified nomenclature system, and
therefore, in 2010, a TPMT nomenclature committee of representatives from around the
world who work in the field was formed with the aim of creating a platform for a full
description of known TPMT alleles and for the numbering of subsequent alleles. The TPMT
nomenclature website (http://www.imh.liu.se/tpmtalleles) was launched in 2011 with the
purpose of managing allele designations and providing a summary of published TPMT
alleles. The nomenclature system chosen was based on the established star allele numbering
system and on recommended genetic variant nomenclature guidelines [29–31].
Currently, the website covers the nomenclature for published TPMT alleles linked to a
designated star allele number, as well as the functionality of the allele. In addition, links to
the National Center for Biotechnology Information single nucleotide polymorphism
database (dbSNP), as well as publications describing the original identification and/or the
characterization of the allele are presented. Researchers are encouraged to submit their own
validated novel genetic variants to dbSNP to obtain a reference SNP identification (rsID) to
aid consistency in genetic variant mapping.
Inclusion criteria for TPMT alleles
The main function of the website is to encourage researchers worldwide to be confident of
which TPMT allele they are referring and to avoid confusion in the literature in the future.
The TPMT nomenclature committee has decided upon inclusion criteria that will help to
maintain this goal, listed 1–8 in Table 2.
Renaming of existing TPMT alleles
To improve the existing nomenclature, the committee reviewed all existing allele numbers,
and for those that are duplicated, the committee has agreed on the renumbering of two
earlier identified and published alleles.
Renaming of TPMT*20/*24 (106G > A in exon III)
The 106G > A SNP in exon 3 was identified during denaturating HPLC screening of the
TPMT gene in 200 Japanese individuals [32] and was numbered TPMT*20. At the same
time, Schaeffeler et al. [33] identified a SNP at position 712 (A > G, rs150900439), and also
numbered it TPMT*20. To address this problem, in 2008 the 106 SNP was renumbered
TPMT*24 [34]. However, at the same time in 2008, Garat et al. [35] presented yet another
SNP at position 537(G > T), which was numbered TPMT*24. The committee has decided
that the SNP at position 106G > A should be designated by the unique star allele number
TPMT*30 (Table 1).
Renaming of TPMT*28 (611T > C in exon IX, rs79901429)
The 611T > C (rs79901429) SNP was identified in a Swedish family with Italian ancestries,
and was numbered TPMT*28 in 2010 [36]. At the same time, Landy et al. [37] described the
identification of a SNP at position 349 (G > C, see Table 1 for comments), which they also
numbered TPMT*28. The committee has decided that the SNP at position 611 should be
assigned a novel star allele number – TPMT*31 (Table 1).
Submission of new alleles
To avoid any confusion in the future, authors are encouraged to submit novel TPMT alleles
(sequence and functionality if available), preferably after a manuscript has been accepted but
before final proofing, to the nomenclature committee through the website for confidential
designation and reservation of a novel allele number by the nomenclature committee, or to
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contact the editor of the committee (corresponding author of the current paper) by ordinary
mail.
To submit a novel TPMT allele to the committee, authors should fill in the form available on
the TPMT nomenclature website, with information regarding, for example, the position of
the variant, gene location (exon/intron, etc.), nucleotide position (e.g. 238), and SNP
flanking sequence. Usage of star allele designations that have not been approved by the
nomenclature committee is strongly discouraged, because of the risk of confusion when two
different alleles are given the same star number. The editors of the TPMT nomenclature
committee (and if appropriate the advisory board, details of which are found on the TPMT
nomenclature website) will review the submission to evaluate whether there are enough data
to support a new allele designation, and will await publishing before making the novel allele
available, ensuring that only peer-reviewed data are published on the TPMT nomenclature
website.
Conclusion
To maintain a common nomenclature system within the field, fellow scientists investigating
TPMT polymorphisms are strongly encouraged to submit novel TPMT allelic variants to the
TPMT nomenclature committee (http://www.imh.liu.se/tpmtalleles) by contacting the
webmaster through the website for the designation and reservation of novel TPMT allele
numbers confidentially.
The authors of this mini-review, some of whom have themselves identified novel TPMT
alleles, are supportive of this new nomenclature system, and will use this system in their
future work. This new nomenclature will also be used at www.pharmgkb.org for
associations between TPMT alleles and drug responses reported in the literature [58] and at
www.LOVD.nl/TPMT, a gene variant database, collecting and displaying all reported
TPMT DNA variants.
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Schematic representation of thiopurine methyltransferase (TPMT) alleles showing affected
exons in stripe pattern, unaffected exons in dark gray, and untranslated parts of exons in
white. The sizes of the exons are proportional to base pair length, whereas the introns are
not. Nucleotide changes in the TPMT gene (given on the negative chromosomal strand,
NCBI reference sequence NM_000367.2) are numbered such that the A in the ATG is + 1.
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TPMT*1 rs2842934 allele Aa Wild type 474Ta – –     –
TPMT*1A ND, G> A – 178C>T Exon I – [38]
TPMT*1S A >G at rs2842934 474T >C Exon VII Ile158Ile [39]
TPMT*2 C>G at rs1800462 238G>C Exon V Ala80Pro [13,14,34,40,41]
TPMT*3A C> T at rs1800460 460G>A Exon VII Ala154Thr [14,34,40–42]
T >C at rs1142345 719A >G Exon X Tyr240Cys     –
TPMT*3B C> T at rs1800460 460G>A Exon VII Ala154Thr [14,34,40,42]
TPMT*3C T >C at rs1142345 719A >G Exon X Tyr240Cys [14,34,40,42]
TPMT*3D C>A at s72552739 292G > T Exon V Glu98Sto [43]
C> T at rs1800460 460G>A Exon VII Ala154Thr     –
T >C at rs1142345 719A >G Exon X Tyr240Cys     –
TPMT*3E A > T at rs3931660 140+ 114T > A Intron III – [44]
T>A at rs12529220 141–101A> T Intron III –     –
A >G at rs2518463 366 + 58T >C Intron IV –     –
C> T at rs1800460 460G>A Exon VII Ala154Thr     –
A >G at rs2842934 474T >C Exon VII Ile158Ile     –
T >C at rs1142345 719A >G Exon X Tyr240Cys     –
TPMT*4 C>T at rs1800584 626-1G> A Intron IX/exon X insplice junction – [43,45]
TPMT*5 A >G at rs72552740 146T >C Exon IV Leu49Ser [34,40,43]
TPMT*6 T >A at rs75543815 539A > T Exon VIII Tyr180Phe [34,40,43]
TPMT*7 A >C at rs72552736 681T >G Exon X His227Gln [34,38,40,43]
TPMT*8 C>T at rs56161402 644G>A Exon X Arg215His [34,40,46]
TPMT*9 T>G at rs151149760 356A >C Exon V Lys119Thr [34,40,47]
TPMT*10 C>G at rs72552737 430G>C Exon VII Gly144Arg [34,40,48,49]
TPMT*11 C>T at rs72552738 395G > A Exon VI Cys132Tyr [34,40,50]
TPMT*12 ND, G> A 374C >T Exon VI Ser125Leu [34,40,49]
TPMT*13 T> A at rs72552742 83A >T Exon III Glu28Val [34,40,49]
TPMT*14 T>C at rs9333569 1A >G Exon III Met1Val [34,51]
TPMT*15 C>T at rs9333570 495-1G > A Intron VII/exon VIIIin splice junction – [51]
TPMT*16 C> T at rs144041067 488G>A Exon VII Arg163His [34,47,52]
TPMT*17 ND, G>C 124C >G Exon III Gln42Glu [34,47]
TPMT*18 ND, C> T 211G >A Exon IV Gly71Arg [34,47]
TPMT*19 ND, T>G 365A>C Exon V Lys122Thr [34,52]
TPMT*20 T>C at rs150900439 712A >G Exon X Lys238Glu [33,34]


































TPMT*21 G>C at rs200591577 205C >G Exon IV Leu69Val [33,34]
TPMT*22 ND, C>G 488G>C Exon VII Arg163Pro [33,34]
TPMT*23 G>C at rs74423290 500C >G Exon VIII Ala167Gly [53]
TPMT*24 C> A at rs6921269 537G> T Exon VIII Gln179His [35]
TPMT*25 ND, A >G 634T >C Exon X Cys212Arg [35]
TPMT*26 A >G at rs72556347 622T>C Exon IX Phe208Leu [54]
TPMT*27 ND, A >C 319T >G Exon V Tyr107Asp [55]
TPMT*28 ND, C>G 349G>Cb Exon V Gly117Arg [37]
TPMT*29 A >G at rs267607275 2T >C Exon III Met1Thr [56]
TPMT*30 Old TPMT*20/*24, ND, C> T 106G> A Exon III Gly36Ser [32,34]
TPMT*31 Old TPMT*28 A >G atrs79901429 611T>C Exon IX Ile204Thr [36]
TPMT*32 C> T at rs115106679 340G>A Exon V Glu114Lys [57]
TPMT*33 G> A at rs112339338 487C>T Exon VII Arg163Cys [57]
TPMT*34 G> A at rs111901354 244C>T Exon V Arg82Trp [57]
The table defines all the single nucleotide polymorphisms (SNPs) in TPMT as of January 2013.
dbSNP, single nucleotide polymorphism database; ND, not reported to dbSNP; TPMT, thiopurine methyltransferase.
a
dbSNP reports G> A at this position: however, the TPMT nomenclature committee has defined wild type as having allele A at this position
(positive chromosomal strand) and the *1S allele as having allele G at this position (positive chromosomal strand).
b
Incorrect nucleotide substitutions are given in Landy et al.’s [37] study: the corrected nucleotide substitution is included in the table (T. Marinaki,
14 September 2012, personal communication).
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Table 2
Inclusion criteria for TPMT alleles to be assigned a unique identity and to be included on the TPMT websitea
(1) On the TPMT nomenclature website, only human TPMT alleles are considered
(2) The gene and allele are separated by an asterisk followed by Arabic numerals
 (e.g. TPMT*1, TPMT*3)
(3) Additional nucleotide changes and combinations of nucleotide changes,
 including silent mutations in the gene, will be assigned letters (e.g. *1A, *1S)
(4) To be assigned as a unique allele, it should contain nucleotide changes that
 have been shown to affect transcription, splicing, translation, post-transcriptional
 or post-translational modifications or result in at least one amino
 acid change
(5) Numbering of nucleotides in the allele should be as described in Antonarakis
 and the NomenclatureWorking Group [30]. In the cDNA sequence, the base A
 in the initiation codon ATG is denoted as + 1 and the base before A is
 numbered as − 1
(6) Submission of new alleles should be done with information sufficient to fulfill
 the criteria to be assigned a unique allele (as under criterion 4 above) or letter
 (as described under criterion 3 above). For incorporation into the website as a
 unique allele, all exons and exon–intron borders should have been sequenced.
 If a new allele has been detected on the cDNA level, verification of the
 mutation(s) on the genomic level is necessary. For acceptance of a new SNP
 given a separate letter (criterion 3), evidence for its presence on the genomic
 level is necessary
(7) No temporary allelic numbers or letters are provided, and information about
 any new allele submitted will continuously be published on the website. In case
 an author does not want to release the information on the website before
 publication, the webmaster can usually provide him or her with an allelic
 designation but not release the information on the website until the manuscript
 has been accepted or published
(8) Any novel SNPs should be submitted to dbSNP (NCBI) after TPMT allele
 designation to obtain a unique rsID for marker mapping – this rsID should then
 be submitted to the website to be added to the table
dbSNP, single nucleotide polymorphism database; TPMT, thiopurine methyltransferase.
a
http://www.imh.liu.se/tpmtpalleles
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